Archive

Drug-related calls received at National Poisons Information Centre, India: A 5-year retrospective record-based study.

Drug-related calls were 24% of total calls; 99% were made by treating physicians. Calls increased during Covid-19, with more calls for children and adolescents and fewer for infants; males were 57% and females 41%.

Medicine · National medical journal of India · 1 Sept

McKesson confirms cybersecurity incident as hackers claim millions of patient records stolen

Patient data may be exposed; verify your practice's third-party vendor security and inform patients of potential risks.

General Medicine · Fierce Healthcare · 31 Aug

UPDATED: Novartis halts autoimmune CAR-T trials after 3 deaths, as BMS also pauses studies

If you prescribe CAR-T for autoimmune conditions, expect regulatory scrutiny and enrollment holds—reassess patient risk and alternatives.

General Medicine · Fierce Biotech · 31 Aug

Docs are seeing more patients influenced by mis- and disinformation. What can they do about it?

Prepare to spend more visit time correcting false beliefs; consider brief motivational interviewing and trusted sources to counter harm.

General Medicine · Fierce Healthcare · 31 Aug

ESC: Alnylam's next-gen silencer sees silver linings after fallout of AZ, Ionis trial in ATTR-CM

For cardiologists managing ATTR-CM, this suggests RNAi may still benefit patients on tafamidis despite the Wainua failure—watch for confirmatory data.

Cardiology · Fierce Biotech · 31 Aug

Solera Health adds Noom to weight management offerings

Expands patient access to structured weight-loss programs and GLP-1 support, potentially improving adherence and outcomes in obesity care.

Endocrinology · Fierce Healthcare · 31 Aug

ESC26: AstraZeneca's heart failure drug shows promise in ph. 2 trial

Oral relaxin agonist improved cardiac function in chronic heart failure—watch for a potential new add-on beyond standard therapy.

Cardiology · Fierce Biotech · 31 Aug

Eli Lilly inks $2.88B Merida buyout for autoimmune drugs against rogue antibodies

Watch for a new class that removes pathogenic autoantibodies—could shift refractory autoimmune management beyond broad immunosuppression.

General Medicine · Fierce Biotech · 31 Aug

Natera teams with Angiex on cancer drug trial monitoring

Signatera may let you track molecular response to Angiex's investigational therapy, guiding earlier treatment decisions in your cancer patients.

Oncology · Fierce Biotech · 31 Aug

Targeted left ventricular lead placement in biventricular pacing for heart failure: a national, multicentre, double-blind, randomised controlled trial in Denmark.

Primary endpoint occurred in 139/499 (28%) intervention vs 128/501 (26%) control (HR 1.10, 95% CI 0.86-1.39; p=0.45). No benefit.

Cardiology · Lancet · 31 Aug

Catheter-Directed Thrombolysis in Intermediate-High-Risk Pulmonary Embolism.

Primary composite event occurred in 2/280 (0.7%) thrombolysis vs 19/278 (6.8%) standard care (RR 0.10, 95% CI 0.02-0.44, P<0.001), driven by reduced cardiorespiratory decompensation. Major bleeding 1.4% vs 2.2% (P=0.54).

Cardiology · NEJM · 31 Aug

Short-term effects of combinations of heart failure therapies on blood pressure, kidney function and serum potassium.

In HFrEF, ARNI+SGLT2i+sMRA reduced SBP by -9.2 (-10.6 to -7.8) mmHg, eGFR by -6.8 (-7.9 to -5.4) ml/min/m2, increased potassium by +0.30 (0.25-0.35) mmol/l. In HFmrEF/HFpEF, SGLT2i+sMRA reduced SBP -5.9 (-7.3 to -4.6) mmHg, eGFR -7.7 (-8.9 to -6.4), potassium +0.34 (0.29-0.38).

Cardiology · Nature Medicine · 31 Aug

FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder

For patients with polycythemia vera, rusfertide offers a new option to control red cell production, potentially reducing phlebotomy burden.

Oncology · FDA — Press Announcements · 29 Aug

BioNTech-Genentech cancer vax records more deaths than control in scrapped ph. 2 test

Adjuvant-only mRNA vaccines may harm; check trial arms before offering off-protocol, especially after Keytruda-paired successes.

Oncology · Fierce Biotech · 28 Aug

Why Roche is 'really excited' about a UCN2 analog for obesity after seeing preclinical data

A UCN2 analog may preserve lean muscle during weight loss—unlike GLP-1s—so watch for trials if you manage obesity.

Endocrinology · Fierce Biotech · 28 Aug

FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults

First oral option for adult dermatomyositis; consider as an alternative to chronic steroids or immunosuppressants in refractory cases.

General Medicine · FDA — Press Announcements · 28 Aug

FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

For patients with KRAS-mutant metastatic pancreatic cancer, this RAS inhibitor offers a new targeted option where chemotherapy has been the only mainstay.

Oncology · FDA — Press Announcements · 26 Aug

Critical care utilisation, and outcomes of critically ill obstetric patients in India: a multicentre ICU registry study (2019-2024).

Obstetric ICU mortality was 3.3% versus 7.9% in non-obstetric women (ASD 0.2). Public ICUs had higher crude mortality (6.4% vs 2.1%) but comparable risk-adjusted outcomes.

Obstetrics & Gynaecology · Lancet regional health. Southeast Asia · 26 Aug

FDA Authorizes First Wearable Device That Continuously Monitors Both Ketone Levels and Blood Sugar

For your diabetic patients, this single wearable replaces separate glucose and ketone sensors, enabling earlier detection of ketoacidosis risk.

Endocrinology · FDA — Press Announcements · 25 Aug

Antimicrobial susceptibility of priority bacterial pathogens from laboratory samples in Timor-Leste: a retrospective analysis of database (2020-2025).

Ceftriaxone susceptibility was 65% (410/631) in E. coli and 25% (135/541) in K. pneumoniae. Meropenem susceptibility in E. coli fell from 100% (33/33) in 2020 to 87% (155/178) in 2024 (p=0.0002).

General Medicine · Lancet regional health. Southeast Asia · 20 Aug

FDA Approves First Therapy for Patients aged 8 years and older with Glycogen Storage Disease Type Ia

First gene therapy for GSDIa; consider referring eligible patients aged 8+ for this one-time option to reduce metabolic crises.

General Medicine · FDA — Press Announcements · 20 Aug

FDA Authorizes First-Of-Its-Kind Robotic Blood Draw Device

Automates phlebotomy, reducing needle-stick errors and freeing staff—consider workflow impact if adopted in Indian hospitals.

General Medicine · FDA — Press Announcements · 19 Aug

FDA Seeks Public Feedback to Inform Regulatory Approach for Generative AI-Enabled Medical Devices

Shaping FDA rules for generative AI devices will influence global standards, affecting your future adoption of AI tools in practice.

Medicine · FDA — Press Announcements · 18 Aug

India's participatory approach to developing a national AI strategy for health: lessons for collective learning.

India's SAHI roadmap will shape how AI triage, imaging and decision tools reach your clinic, so knowing its priorities tells you what adoption support is coming.

General Medicine · Lancet regional health. Southeast Asia · 16 Aug

Trends of congenital rubella syndrome among infants (0-11 months old) in India: a multicentre hospital-based sentinel surveillance (2016-2025).

Laboratory-confirmed CRS in 583 of 8953 (6.5%). Proportion declined from 24.9% in 2017 to 2.5% in 2025. One-year mortality 32.2% (95% CI 26.7-38.4).

Medicine · Lancet regional health. Southeast Asia · 11 Aug

FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma

For patients with advanced melanoma who've exhausted checkpoint inhibitors, this new oncolytic virus offers a novel mechanism and a new option.

Oncology · FDA — Press Announcements · 7 Aug

Factors influencing antimicrobial stewardship implementation in healthcare facilities in four countries of Southeast Asia: a mixed-methods study (2022-23).

All four countries had national AMS policies; two had financing mechanisms. Mean facility G-ASET score was 241/335 (72%); training and education lowest at 17/25 (66%), tracking, monitoring, and reporting highest at 56/75 (75%).

Medicine · Lancet regional health. Southeast Asia · 6 Aug

FDA Approves First Drug to Treat the Full Range of Narcolepsy Type 1 Symptoms

For adults with narcolepsy type 1, this first full-spectrum oral option may reduce cataplexy and sleepiness, offering an alternative to stimulants and sodium oxybate.

Neurology · FDA — Press Announcements · 6 Aug

Two-day versus three-day systemic antibiotic prophylaxis for Gustilo-Anderson type IIIA and IIIB open tibial fractures (PROACT): a randomised controlled trial.

90-day surgical-site infection occurred in 15/104 (14%) with 2-day vs 18/100 (18%) with 3-day; risk difference -3.6% (95% CI -14.0 to 7.0, p=0.60). No significant difference.

Orthopaedics · Lancet regional health. Southeast Asia · 1 Aug

Mortality and cost of therapy of carbapenem susceptible vs resistant Gram-negative infections among hospitalised patients in India: a multicentric surveillance (2022-2025).

Carbapenem resistance increased mortality risk: E. coli RR 1.41 (95% CI 1.13-1.70), K. pneumoniae RR 1.33 (1.18-1.51), A. baumannii RR 1.16 (1.02-1.34), P. aeruginosa RR 1.43 (1.15-1.92). Bloodstream CR non-fermenter mortality 46.4-50.8%.

Medicine · Lancet regional health. Southeast Asia · 30 Jul

FDA Licenses First-Ever Freeze-Dried Plasma Product in the U.S.

Gives you a shelf-stable plasma option when conventional products are unavailable—useful in remote or austere settings for adult transfusion.

General Medicine · FDA — Press Announcements · 29 Jul

Antimicrobial stewardship programme in Sri Lanka: insights from early implementation experience (2024-2025).

Implementation exceeded 50% across all key performance indicators. AWaRe classification integration had the highest uptake at 74%; functional AMS teams and point prevalence surveys reached 52%.

General Medicine · Lancet regional health. Southeast Asia · 27 Jul

Challenges in access to novel IgA nephropathy therapeutics in South Asia.

No new data. Most South Asian IgA nephropathy patients remain on supportive care and conventional immunosuppressives; barriers cited include specialist shortage, delayed diagnosis, high treatment costs, no universal health coverage, regulatory hurdles and trial underrepresentation.

General Medicine · Lancet regional health. Southeast Asia · 22 Jul